Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 5/20 | 0.37 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.37 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.37 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.33 |
| ▸ | CDK2 | P24941 | 2/20 | 0.32 |
| ▸ | CDK1 | P06493 | 1/20 | 0.32 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.32 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.32 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.32 |
| ▸ | TLR8 | Q9NR97 | 2/20 | 0.31 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.31 |
| ▸ | FFAR2 | O15552 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12157746 | 0.89 | TLR7 (0.40) | TLR7MCHR1TLR8 | |
| SCHEMBL1840777 | 0.89 | TLR7 (0.40) | TLR7MCHR1TLR8 | |
| SCHEMBL12157560 | 0.89 | TLR7 (0.40) | TLR7MCHR1TLR8 | |
| SCHEMBL12157596 | 0.87 | MCHR1 (0.36) | TLR7MCHR1 | |
| SCHEMBL10121645 | 0.87 | ADORA2A (0.31) | TLR7ADORA2AADORA2B | |
| SCHEMBL10121637 | 0.87 | TLR7 (0.41) | TLR7TLR8 | |
| SCHEMBL2201765 | 0.82 | TLR8 (0.35) | ADORA2AADORA2BMCHR1CDK2CDK1 | |
| SCHEMBL1146282 | 0.81 | PDE4B (0.34) | TLR7ADORA2AADORA2B | |
| Trifluoroacetic Acid SCHEMBL566045 | 0.79 | TLR7 (0.36) | TLR7MCHR1TLR8 | |
| Trifluoroacetic Acid SCHEMBL29697218 | 0.79 | TLR7 (0.36) | TLR7MCHR1TLR8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190038631-A1 | 6-AMINO-PURIN-8-ONE COMPOUNDS | GLAXOSMITHKLINE LLC | 2019-02-07 | — | — | US | disclosed |
| EP-3336089-A1 | PURINE DERIVATIVES FOR USE IN THE TREATMENT OF ALLERGIC, INFLAMMATORY AND INFECTIOUS DISEASES | GlaxoSmithKline LLC (US) | 2018-06-20 | — | — | EP | disclosed |
| US-20180117048-A1 | 6-AMINO-PURIN-8-ONE COMPOUNDS | GLAXOSMITHKLINE LLC | 2018-05-03 | — | — | US | disclosed |
| US-20180117048-A1 | 6-AMINO-PURIN-8-ONE COMPOUNDS | GLAXOSMITHKLINE LLC | 2018-05-03 | — | — | US | disclosed |
| US-9877968-B2 | 6-amino-purin-8-one compounds | GLAXOSMITHKLINE LLC (US) | 2018-01-30 | — | — | US | disclosed |
| US-9877968-B2 | 6-amino-purin-8-one compounds | GLAXOSMITHKLINE LLC (US) | 2018-01-30 | — | — | US | disclosed |
| US-20160228445-A1 | 6-AMINO-PURIN-8-ONE COMPOUNDS | GLAXOSMITHKLINE LLC | 2016-08-11 | — | — | US | disclosed |
| US-20160228445-A1 | 6-AMINO-PURIN-8-ONE COMPOUNDS | GLAXOSMITHKLINE LLC | 2016-08-11 | — | — | US | disclosed |
| US-9346806-B2 | 6-amino-purin-8-one compounds | GLAXOSMITHKLINE LLC (US) | 2016-05-24 | — | — | US | disclosed |
| US-9346806-B2 | 6-amino-purin-8-one compounds | GLAXOSMITHKLINE LLC (US) | 2016-05-24 | — | — | US | disclosed |
| US-20120035193-A1 | 6-AMINO-PURIN-8-ONE COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2012-02-09 | — | — | US | disclosed |
| US-20120035193-A1 | 6-AMINO-PURIN-8-ONE COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2012-02-09 | — | — | US | disclosed |
| US-8067426-B2 | 6-amino-purin-8-one compounds | GLAXOSMITHKLINE LLC (US) | 2011-11-29 | — | — | US | disclosed |
| US-8067426-B2 | 6-amino-purin-8-one compounds | GLAXOSMITHKLINE LLC (US) | 2011-11-29 | — | — | US | disclosed |
| US-20110229500-A1 | PURINE DERIVATIVES FOR USE IN THE TREATMENT OF ALLERGIC, INFLAMMATORY AND INFECTIOUS DISEASES | GLAXOSMITHKLINE LLC (US) | 2011-09-22 | — | — | US | disclosed |
| US-20110229500-A1 | PURINE DERIVATIVES FOR USE IN THE TREATMENT OF ALLERGIC, INFLAMMATORY AND INFECTIOUS DISEASES | GLAXOSMITHKLINE LLC (US) | 2011-09-22 | — | — | US | disclosed |
| US-20110135671-A1 | PURINE DERIVATIVES FOR USE IN THE TREATMENT OF ALLERGIC, INFLAMMATORY AND INFECTIOUS DISEASES | GLAXOSMITHKLINE LLC (US) | 2011-06-09 | — | — | US | disclosed |
| US-20110135671-A1 | PURINE DERIVATIVES FOR USE IN THE TREATMENT OF ALLERGIC, INFLAMMATORY AND INFECTIOUS DISEASES | GLAXOSMITHKLINE LLC (US) | 2011-06-09 | — | — | US | disclosed |
| US-20100075995-A1 | COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2010-03-25 | — | — | US | disclosed |
| US-20100075995-A1 | COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2010-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110229500-A1 | PURINE DERIVATIVES FOR USE IN THE TREATMENT OF ALLERGIC, INFLAMMATORY AND INFECTIOUS DISEASES | IFNAR1, IFNG, STING1 | TLR7 10/4885ADORA2A 14/4885ADORA2B 20/4885 |
| US-20110135671-A1 | PURINE DERIVATIVES FOR USE IN THE TREATMENT OF ALLERGIC, INFLAMMATORY AND INFECTIOUS DISEASES | IFNG, IFNAR1, STING1 | TLR7 19/4885ADORA2A 16/4885ADORA2B 24/4885 |
| US-20190038631-A1 | 6-AMINO-PURIN-8-ONE COMPOUNDS | IFNG, IFNAR1, IRF3 | TLR7 7/4885ADORA2A 78/4885ADORA2B 46/4885 |
| US-20120035193-A1 | 6-AMINO-PURIN-8-ONE COMPOUNDS | IFNG, IFNAR1, IRF3 | TLR7 7/4885ADORA2A 78/4885ADORA2B 46/4885 |
| US-20180117048-A1 | 6-AMINO-PURIN-8-ONE COMPOUNDS | IFNG, IFNAR1, IRF3 | TLR7 7/4885ADORA2A 78/4885ADORA2B 46/4885 |
| US-20100075995-A1 | COMPOUNDS | IFNG, IRF3, IFNAR1 | TLR7 8/4885ADORA2A 1039/4885ADORA2B 631/4885 |
| US-20160228445-A1 | 6-AMINO-PURIN-8-ONE COMPOUNDS | IFNG, IFNAR1, IRF3 | TLR7 7/4885ADORA2A 78/4885ADORA2B 46/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.